Ensembles of endothelial and mural cells promote angiogenesis in prenatal human brain

1. Download : Download high-res image (311KB)
2. Download : Download full-size image

     

人体动脉血气波浪式变化特点的实验证据—同时间动、静脉血波浪式变化幅度的不同*

目的: 人动脉血来源是右心系统并在肺脏进行气体交换的静脉血,右心系统的静脉血是否存在波浪式信号目前尚没有证据支持,本研究旨在对比同时间动、静脉血中信号的连续变化特点。方法: 选择心功能正常,需要连续监测动脉血流动力学变化的患者6 例,4男2女,年龄（59.00±16.64） 岁,体质量（71.67±10.37）kg,左心射血分数（LVEF）（61.33±2.16)%。患者签署知情同意书后,选择心功能正常需要监测动、静脉血流动力学变化的患者6 例,连续同时桡动脉、颈内静脉逐搏取血,测定PaO₂。选取2个典型呼吸周期,用于分析同时段动、静脉血气的波浪式变化。分别比较患者血氧分压最高和最低值,以验证同时段动、静脉血气是否都存在周期性波浪式信号变化。此外,将患者动脉、静脉血气周期性波浪式信号的变化幅度进行统计学t 检验分析,比较有无差异。结果: 共6例患者,抽取动、静脉血液充满肝素化细长塑化管需要15~16次心跳,即取血需要15~16次心跳,全部覆盖超过2个呼吸周期。所有患者动脉血气中PaO₂均呈现明显的波浪式变化（P<0.05）,幅度是（9.96±5.18）mmHg,是均值的（8.09±2.43）%。患者静脉血气中PaO₂波动幅度并不明显,为（1.63±0.41）mmHg,是均值的（3.91±1.22）%,与动脉血气组相比有明显统计学差异（P<0.05）。结论: 采用同时连续逐搏动、静脉取血血气分析法证实,患者自主呼吸时动脉血气有明显的周期性波浪式变化信号,而静脉血气几乎没有周期性波浪式变化信号（很弱）,说明动脉血气波浪式信号主要是由于肺通气过程中吸气和呼气期产生肺泡中氧分压规律性上升和下降,通过离开肺毛细血管与肺泡氧气压力平衡的动脉化血液,经过左心室搏血进入动脉血管系统所致。     

血清TM、P-selectin、HDL-C以及凝血功能指标与创伤性骨折患者术后深静脉血栓形成的关系研究

摘要 目的：探讨血清血栓调节蛋白（TM）、P-选择素（P-selectin）、高密度脂蛋白（HDL-C）以及凝血功能指标与创伤性骨折患者术后深静脉血栓形成（DVT）的关系。方法：选择2018年1月至2020年1月我院收治的术后发生DVT的创伤性骨折患者100例作为DVT组,同期术后未发生DVT的创伤性骨折患者100例作为无DVT组,比较两组血清TM、P-selectin、HDL-C、血浆凝血功能指标[凝血酶时间（TT）、凝血酶原时间（PT）、活化部分凝血酶时间（APTT）、纤维蛋白原（FIB）、D-二聚体（D-D）],应用Pearson相关性分析血清TM、P-selectin、HDL-C与凝血功能指标的相关性,应用多因素Logistic回归分析创伤性骨折患者术后DVT的影响因素。结果：DVT组血清TM、P-selectin、血浆D-D、FIB水平、年龄≥60岁比例高于无DVT组,血清HDL-C水平低于无DVT组（P＜0.05）。DVT组血清TM和P-selectin与血浆D-D、FIB呈正相关（P＜0.05）,血清HDL-C与血浆D-D、FIB呈负相关（P＜0.05）。多因素Logistic回归分析显示,年龄≥60岁、血清TM≥9.50 IU/mL、P-selectin ≥70.00 ng/mL、HDL-C<1.00 mmol/L、血浆D-D≥700.00 μg/L、FIB≥4.00 g/L是创伤性骨折患者术后DVT的危险因素（P＜0.05）。结论：创伤性骨折患者术后发生DVT患者血清TM、P-selectin较无DVT患者升高,HDL-C较无DVT患者降低,联合检测血清TM、P-selectin、HDL-C和凝血功能指标可能有助于降低DVT的发生风险。     

Pulmonary embolism and 3-month outcomes in 4036 patients with venous thromboembolism and chronic obstructive pulmonary disease: data from the RIETE registry

Background

Patients with chronic obstructive pulmonary disease (COPD) have a modified clinical presentation of venous thromboembolism (VTE) but also a worse prognosis than non-COPD patients with VTE. As it may induce therapeutic modifications, we evaluated the influence of the initial VTE presentation on the 3-month outcomes in COPD patients.

Methods

COPD patients included in the on-going world-wide RIETE Registry were studied. The rate of pulmonary embolism (PE), major bleeding and death during the first 3 months in COPD patients were compared according to their initial clinical presentation (acute PE or deep vein thrombosis (DVT)).

Results

Of the 4036 COPD patients included, 2452 (61%; 95% CI: 59.2-62.3) initially presented with PE. PE as the first VTE recurrence occurred in 116 patients, major bleeding in 101 patients and mortality in 443 patients (Fatal PE: first cause of death). Multivariate analysis confirmed that presenting with PE was associated with higher risk of VTE recurrence as PE (OR, 2.04; 95% CI: 1.11-3.72) and higher risk of fatal PE (OR, 7.77; 95% CI: 2.92-15.7).

Conclusions

COPD patients presenting with PE have an increased risk for PE recurrences and fatal PE compared with those presenting with DVT alone. More efficient therapy is needed in this subtype of patients.     

Circulating and tissue microRNAs as a potential diagnostic biomarker in patients with thrombotic events

Venous and arterial thrombosis are conditions that have a considerable burden if left untreated. The hypoxia-induced by the occluded vessel can disrupt the circulation of any organ, the cornerstone of treating thrombosis is rapid diagnosis and appropriate treatment. Diagnosis of thrombosis may be made by using laboratory tests or imaging techniques in individuals who have clinical manifestations of a thrombotic event. The use of serum micro ribonucleic acids (RNAs) has recently been applied to the diagnosis of thrombosis. These small RNA molecules are emerging as new diagnostic markers but have had very limited applications in vascular disease. Most of the articles provided various microRNAs with different levels of accuracy. However, there remains a lack of an appropriate panel of the most specific microRNA in the literature. The purpose of the present review was to summarize the existing data on the use of microRNAs as a diagnostic biomarker for venous thrombosis.     

A phase II randomized clinical trial for the treatment of recalcitrant chronic leg ulcers using centrifuged adipose tissue containing progenitor cells

Background aims

Preclinical and observational reports indicate that adipose tissue (AT) is a safe and promising tool to treat non-healing venous leg ulcers (VLUs).

静脉导管留置及胸腔注射尿激酶治疗结核性胸腔积液影响

探讨中心静脉导管胸腔穿刺留置抽液联合胸腔内注入尿激酶(urokinase,UK)治疗结核性渗出性胸膜炎对胸膜肥厚、粘连的预防作用。方法:将52例收治的结核性渗出性胸膜炎所致大量胸腔积液患者随机分为治疗组(27例)和对照组(25例),对照组给于常规抗结核以及传统单纯胸腔穿刺抽液(每周3次)等治疗;全身结核中毒症状严重者,予口服泼尼松30mg．d-1,每周减量5～10mg,疗程约4～6周。在以上药物治疗同时,治疗组第一次穿刺时使用一次性中心静脉导管代替传统胸穿针穿刺置入并保留于胸腔,抽液后从导管注入尿激酶10～20万U,保留24小时后再次抽液;可以再次或多次使用尿激酶10万u注入胸腔;此后不定时抽液,经B超证实抽尽胸水后拔除导管。结果:治疗组住院时间(12．3±6．6)天,住院费用(2219．5±1171．9)元,治疗后第三个月的胸膜厚度(1．00±0．23)mm,无病例发生胸膜增厚、粘连及包裹性胸腔积液。对照组住院时间(20．4±7．9)天,住院费用(2721．9±1711．7)元,治疗后第三个月胸膜厚度(2．1±0．31)mm,另有3例发生胸膜增厚、粘连,2例形成包裹性胸腔积液。各项指标对比差异有显著性。结论:中心静脉导管胸腔穿刺留置抽液及尿激酶胸腔内保留注射治疗结核性胸腔积液具有简便、安全、创伤少、疗效确切;缩短住院时间,降低住院费用;且能有效预防胸膜肥厚和粘连发生。值得临床推广应用。     

Allosteric Inhibition as a New Mode of Action for BAY 1213790, a Neutralizing Antibody Targeting the Activated Form of Coagulation Factor XI

Factor XI (FXI), the zymogen of activated FXI (FXIa), is an attractive target for novel anticoagulants because FXI inhibition offers the potential to reduce thrombosis risk while minimizing the risk of bleeding. BAY 1213790, a novel anti-FXIa antibody, was generated using phage display technology. Crystal structure analysis of the FXIa–BAY 1213790 complex demonstrated that the tyrosine-rich complementarity-determining region 3 loop of the heavy chain of BAY 1213790 penetrated deepest into the FXIa binding epitope, forming a network of favorable interactions including a direct hydrogen bond from Tyr102 to the Gln451 sidechain (2.9 Å). The newly discovered binding epitope caused a structural rearrangement of the FXIa active site, revealing a novel allosteric mechanism of FXIa inhibition by BAY 1213790. BAY 1213790 specifically inhibited FXIa with a binding affinity of 2.4 nM, and in human plasma, prolonged activated partial thromboplastin time and inhibited thrombin generation in a concentration-dependent manner.     

Bacillus cereus biofilm formation on central venous catheters of hospitalised cardiac patients

Formation of bacterial biofilms is a risk with many in situ medical devices. Biofilm-forming Bacillus species are associated with potentially life-threatening catheter-related blood stream infections in immunocompromised patients. Here, bacteria were isolated from biofilm-like structures within the lumen of central venous catheters (CVCs) from two patients admitted to cardiac hospital wards. Isolates belonged to the Bacillus cereus group, exhibited strong biofilm formation propensity, and mapped phylogenetically close to the B. cereus emetic cluster. Together, whole genome sequencing and quantitative PCR confirmed that the isolates constituted the same strain and possessed a range of genes important for and up-regulated during biofilm formation. Antimicrobial susceptibility testing demonstrated resistance to trimethoprim-sulphamethoxazole, clindamycin, penicillin and ampicillin. Inspection of the genome revealed several chromosomal β-lactamase genes and a sulphonamide resistant variant of folP. This study clearly shows that B. cereus persisting in hospital ward environments may constitute a risk factor from repeated contamination of CVCs.